146 related articles for article (PubMed ID: 22120760)
1. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas.
Hightower E; Cabanillas ME; Fuller GN; McCutcheon IE; Hess KR; Shah K; Waguespack SG; Corley LJ; Devin JK
Pituitary; 2012 Dec; 15(4):556-61. PubMed ID: 22120760
[TBL] [Abstract][Full Text] [Related]
2. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
3. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K
Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322
[TBL] [Abstract][Full Text] [Related]
4. Predicting short-term recurrence in pituitary adenomas: Phosphohistone-H3 (Ser 10) proves an effective biomarker.
Li C; Wei L; Li L; Wang J; Li R; Zhang Q; Zhou D
Clin Neuropathol; 2020; 39(2):70-79. PubMed ID: 31724532
[TBL] [Abstract][Full Text] [Related]
5. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH
Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.
Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P
Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of phospho-histone H3 in prostate carcinoma.
Nowak M; Svensson MA; Carlsson J; Vogel W; Kebschull M; Wernert N; Kristiansen G; Andrén O; Braun M; Perner S
World J Urol; 2014 Jun; 32(3):703-7. PubMed ID: 23887713
[TBL] [Abstract][Full Text] [Related]
8. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas.
Hentschel SJ; McCutcheon lE; Moore W; Durity FA
Can J Neurol Sci; 2003 Aug; 30(3):215-9. PubMed ID: 12945944
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
10. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
11. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
13. Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices.
Iwasaki T; Matsushita M; Nonaka D; Kato M; Nagata K; Murakami I; Hayashi K
Pathol Int; 2015 Aug; 65(8):404-9. PubMed ID: 25982855
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated histone H3, Ki-67, p21, fatty acid synthase, and cleaved caspase-3 expression in benign and atypical granular cell tumors.
Kapur P; Rakheja D; Balani JP; Roy LC; Amirkhan RH; Hoang MP
Arch Pathol Lab Med; 2007 Jan; 131(1):57-64. PubMed ID: 17227124
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
16. Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.
Uguen A; Conq G; Doucet L; Talagas M; Costa S; De Braekeleer M; Marcorelles P
Virchows Arch; 2015 Jul; 467(1):47-54. PubMed ID: 25823616
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
20. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
